MADRIGAL PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2011 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Madrigal Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2011 to Q4 2024.
  • Madrigal Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $17.7M, a 19% increase year-over-year.
  • Madrigal Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $79.9M, a 60.6% increase year-over-year.
  • Madrigal Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $79.9M, a 60.6% increase from 2023.
  • Madrigal Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.7M, a 57.3% increase from 2022.
  • Madrigal Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $31.6M, a 17.7% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
* An asterisk sign (*) next to the value indicates that the value is likely invalid.